| 儿童碳青霉烯耐药肠杆菌抗感染药物的研究进展 |
| |
| 引用本文： | 吕鹏,王运红,樊晖晖,马芬芬,张玉,黄怡菲.儿童碳青霉烯耐药肠杆菌抗感染药物的研究进展[J].中国医院药学杂志,2021,41(9):966-970. |
| |
| 作者姓名： | 吕鹏 王运红 樊晖晖 马芬芬 张玉 黄怡菲 |
| |
| 作者单位： | 1. 安徽省太和县人民医院药剂科, 安徽 太和 236600;2. 复旦大学附属浦东医院临床药学室, 上海 201399;3. 华中科技大学同济医学院附属协和医院药学部, 湖北 武汉 430022 |
| |
| 基金项目： | 国家重点研发计划资助项目（编号：2017YFC0909900）；国家自然科学基金青年科学基金项目（编号：81900224） |
| |
| 摘 要： | 随着儿童碳青霉烯耐药肠杆菌的检出率逐渐增加，显著增加患儿死亡率，已成为全球关注的难题。儿童作为特殊人群，可用药物有限，使得治疗更加困难。现有的报道多基于成人的研究结果，尚无完整的针对儿童的治疗方案、剂量推荐、安全性等数据。本文综述了儿童碳青霉烯耐药肠杆菌的流行病学、危险因素及不同耐药机制下抗菌药物的选择，并对已批准用于儿童碳青霉烯耐药肠杆菌感染的抗菌药物（碳青霉烯类、多黏菌素、磷霉素等）及新型β-内酰胺酶抑制剂复方制剂（头孢他啶/阿维巴坦、美罗培南/法硼巴坦、亚胺培南-西司他丁/雷利巴坦）的推荐给药方案逐一进行简介，为临床应用提供参考。
|
| 关 键 词： | 碳青霉烯耐药肠杆菌 儿童 流行病学 抗菌药物 |
| 收稿时间： | 2020-11-09 |
Research progress on anti-infective drugs for carbapenem-resistant Enterobacteriaceae infections in children |
| |
| LV Peng,WANG Yun-hong,FAN Hui-hui,MA Fen-fen,ZHANG Yu,HUANG Yi-fei.Research progress on anti-infective drugs for carbapenem-resistant Enterobacteriaceae infections in children[J].Chinese Journal of Hospital Pharmacy,2021,41(9):966-970. |
| |
| Authors: | LV Peng WANG Yun-hong FAN Hui-hui MA Fen-fen ZHANG Yu HUANG Yi-fei |
| |
| Institution: | 1. Department of Pharmacy, Taihe County People's Hospital, Anhui Taihe 236600, China;2. Department of Clinical Pharmacy, Affiliated Pudong Medical Center, Fudan University, Shanghai 211399, China;3. Department of Pharmacy, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Hubei Wuhan 430022, China |
| |
| Abstract: | Infections due to carbapenem-resistant Enterobacteriaceae(CRE) are increasingly prevalent in children and are associated with significant mortality.Recommendations for antibiotic therapy of CRE infections in children are based upon evidences mostly from adult studies without pediatric-specific effective data and uncertain pediatric dosing regimens and safety data.This review provided evidences on the relevant microbiologic considerations and the selection of antibacterial drugs under different resistance mechanisms for CRE.And we offered an overview on the recommended dosing regimens of antibacterial drugs(carbapenems,polymyxins & fosfomycin) approved for treating CRE infections in children and novel β-lactam-β-lactamase inhibitor(ceftazidime-avibactam,meropenem-vaborbactam,imipenem-cilastatin-relebactam) to provide reference for clinical application. |
| |
| Keywords: | carbapenem-resistant Enterobacteriaceae children epidemiology antibacterial agents |
|
| 点击此处可从《中国医院药学杂志》浏览原始摘要信息 |
| 点击此处可从《中国医院药学杂志》下载免费的PDF全文 |
|
